Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival SignalingLászló G. Puskás, Michael A. James, Imola Mán et al.|Molecular Cancer Therapeutics|2016Cited by 21